CompletedNCT00796640
Official study titleA Comparative Evaluation of the Pharmacokinetics and Pharmacodynamics Under Fasting and Fed Conditions of 2 Paliperidone Extended-release Pellet Formulations With Paliperidone Oral Solution in Healthy Adults
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 18–55
- Countries
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
CompletedNCT01812642
What is this study about?This study evaluated the safety of JNJ-37822681 for people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including AntwerpSchizophreniaMedication studyAges 20–55
- Countries
- Belgium, Germany, Russia, + 2 others
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
CompletedNCT02804568
What is this study about?This study evaluated the safety of ALKS 3831 for people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including Little RockSchizophreniaMedication studyAges 18–55
- Countries
- United States
- Sponsor
- Alkermes, Inc.
CompletedACTRN12619001485123
Official study titleA Phase 1, Two Stage, Double-Blind, Placebo-Controlled Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Oral Etifoxine in Normal Healthy Volunteers
This study has finished and is no longer accepting participants.
In MelbourneAnxietyInterventional studyAges 18–65
- Countries
- Australia
- Sponsor
- Gaba Therapeutics Australia Pty Ltd a subsidiary of Gaba Therapeutics, Inc
TerminatedNCT02827513
Official study titleA Phase 1 Study to Investigate the Safety, Tolerance, Food Effect, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of Extended Release Formulations of Centanafadine (CTN) (Formerly Called EB-1020) in Young Healthy Subjects
This study ended early.
In MelbourneADHDMedication studyAges 18–45
- Countries
- Australia
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)
CompletedEUCTR 2018-001064-30
This study has finished and is no longer accepting participants.
Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.
In BulgariaMental healthHistorical research record
- Countries
- Bulgaria
- Sponsor
- ACADIA Pharmaceuticals Inc.
CompletedACTRN12624000547549
Official study titleA Phase 1, Open-label, Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of a Single Intravenous Infusion of TRP-8803 (Psilocin) in Healthy Adult Participants
This study has finished and is no longer accepting participants.
In AustraliaMental healthInterventional studyAges 18–55
- Countries
- Australia
- Sponsor
- Tryp Therapeutics, Inc.
CompletedACTRN12625001127493
Official study titleA Phase 1, Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Study to Assess the Pharmacokinetics, Safety and Tolerability of CBD Inhalation Aerosol in Healthy Adult Volunteers
This study has finished and is no longer accepting participants.
In AustraliaAnxietyInterventional studyAges 18–65
- Countries
- Australia
- Sponsor
- InhaleRx Ltd.
CompletedEUCTR 2018-004208-20
This study has finished and is no longer accepting participants.
Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.
In NetherlandsDepressionHistorical research record
- Countries
- Netherlands
- Sponsor
- Gh Research Limited
CompletedACTRN12618001042235
Official study titleA Phase 2a Proof-of-Concept Study of R-107 for the Treatment of Refractory Major Depressive Disorder
This study has finished and is no longer accepting participants.
Multiple locations, including CamperdownDepressionInterventional studyAges 18–80
- Countries
- Australia, New Zealand, Singapore, + 1 other
- Sponsor
- Douglas Pharmaceuticals Ltd.
TerminatedEUCTR 2021-006861-39
Official study titleA Phase 2 Clinical Trial of GH001 in Patients with Bipolar II Disorder and a Current Major Depressive Episode (GH001-BD-202)
Original registry wording; source language not specified.
This study ended early.
Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.
In GermanyBipolarity, DepressionHistorical research record
- Countries
- Germany, Netherlands
- Sponsor
- GH Research Ireland Limited
CompletedEUCTR 2021-006879-42
This study has finished and is no longer accepting participants.
Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.
In NetherlandsDepressionHistorical research record
- Countries
- Netherlands
- Sponsor
- GH Research Ireland Limited
